MA37742A1 - Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments - Google Patents
Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicamentsInfo
- Publication number
- MA37742A1 MA37742A1 MA37742A MA37742A MA37742A1 MA 37742 A1 MA37742 A1 MA 37742A1 MA 37742 A MA37742 A MA 37742A MA 37742 A MA37742 A MA 37742A MA 37742 A1 MA37742 A1 MA 37742A1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- medicaments
- tetraene
- derivatives
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des inhibiteurs de akr1c3 et des procédés pour les préparer, ainsi que leur utilisation pour traiter et/ou prévenir des maladies et pour fabriquer des médicaments destinés à traiter et/ou à prévenir des maladies, en particulier les troubles hémorragiques et l'endométriose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012211970 | 2012-07-10 | ||
PCT/EP2013/064257 WO2014009274A1 (fr) | 2012-07-10 | 2013-07-05 | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37742A1 true MA37742A1 (fr) | 2016-05-31 |
MA37742B1 MA37742B1 (fr) | 2016-12-30 |
Family
ID=48748225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37742A MA37742B1 (fr) | 2012-07-10 | 2015-01-07 | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments |
Country Status (28)
Country | Link |
---|---|
US (1) | US9512169B2 (fr) |
EP (1) | EP2872524B1 (fr) |
JP (1) | JP6196302B2 (fr) |
KR (1) | KR20150036319A (fr) |
CN (1) | CN104428309B (fr) |
AP (1) | AP2014008179A0 (fr) |
AR (1) | AR092025A1 (fr) |
AU (1) | AU2013289344A1 (fr) |
BR (1) | BR112015000443A2 (fr) |
CA (1) | CA2878485A1 (fr) |
CL (1) | CL2015000039A1 (fr) |
CO (1) | CO7160008A2 (fr) |
CR (1) | CR20150007A (fr) |
DO (1) | DOP2015000005A (fr) |
EA (1) | EA201500112A1 (fr) |
EC (1) | ECSP15000868A (fr) |
ES (1) | ES2603258T3 (fr) |
HK (1) | HK1205743A1 (fr) |
IL (1) | IL236581A0 (fr) |
MA (1) | MA37742B1 (fr) |
MX (1) | MX2015000347A (fr) |
PE (1) | PE20150353A1 (fr) |
PH (1) | PH12015500062A1 (fr) |
TN (1) | TN2015000007A1 (fr) |
TW (1) | TW201402596A (fr) |
UY (1) | UY34899A (fr) |
WO (1) | WO2014009274A1 (fr) |
ZA (1) | ZA201500920B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA38349A1 (fr) * | 2013-02-21 | 2017-02-28 | Bayer Pharma AG | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) |
CN106687471B (zh) * | 2014-09-11 | 2018-10-30 | 拜耳医药股份公司 | 3-氮或者硫取代的雌甾-1,3,5(10),16-四烯akr1c3抑制剂 |
US10167293B2 (en) | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
EP3269373A1 (fr) | 2016-07-11 | 2018-01-17 | Bayer Pharma Aktiengesellschaft | Formes posologiques orales à faible dosage d'un inhibiteur de akr1c3 pour le traitement des maladies |
EP3555067A1 (fr) | 2016-12-19 | 2019-10-23 | Bayer Pharma Aktiengesellschaft | [4-(phénylsulfonyl)pipérazin-1-yl](1h-1,2,3-triazol-4-yl)méthanones |
TW201825478A (zh) | 2016-12-19 | 2018-07-16 | 德商拜耳製藥公司 | [4-(苯基磺醯基)哌嗪-1--基](1h-1,2,3-三唑-4-基)甲酮 |
CA3047196A1 (fr) | 2016-12-19 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones |
EP3421483A1 (fr) | 2017-06-29 | 2019-01-02 | Bayer Pharma Aktiengesellschaft | Nouveaux dérivés 17-beta-hétéroaryle des stéroïdes comme inhibiteurs de akr1c3 |
CN110693892A (zh) * | 2018-07-09 | 2020-01-17 | 深圳艾欣达伟医药科技有限公司 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
CN110272465A (zh) * | 2019-07-15 | 2019-09-24 | 成都贝诺科成生物科技有限公司 | 阿比特龙衍生物、其制备方法与应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
JP2742331B2 (ja) * | 1992-03-31 | 1998-04-22 | ブリテイツシユ・テクノロジー・グループ・リミテツド | 癌治療に有用な17位置換ステロイド |
IL122740A (en) | 1997-01-15 | 2003-09-17 | Akzo Nobel Nv | 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them |
KR20010006118A (ko) | 1997-04-07 | 2001-01-26 | 이곤 이 버그 | 에스트로겐 활성을 갖는 에스트라-5(10),7-디엔 |
MXPA00008868A (es) | 1998-03-11 | 2003-04-25 | Endorech Inc | Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso. |
AU5144999A (en) * | 1998-08-07 | 2000-02-28 | Endorecherche Inc. | Inhibition of type 3 3alpha-hydroxysteroid dehydrogenase |
US6953785B2 (en) * | 2000-04-24 | 2005-10-11 | Kyowa Hakko Kogyo Co., Ltd. | Estra-1,3,5(10)-triene derivatives |
JP2007529426A (ja) | 2004-03-12 | 2007-10-25 | エントレメッド インコーポレイテッド | 抗血管新生薬 |
CA2644809A1 (fr) | 2006-03-02 | 2007-09-07 | Astellas Pharma Inc. | Inhibiteur de la 17 .beta. hsd de type 5 |
MX2009005201A (es) | 2006-11-30 | 2009-05-27 | Solvay Pharm Gmbh | Derivados de estratrieno sustituidos como inhibidores de 17beta hsd. |
CA2673307A1 (fr) | 2006-12-22 | 2008-07-03 | F. Hoffman-La Roche Ag | Derives de spiropiperidine |
WO2009014150A1 (fr) | 2007-07-24 | 2009-01-29 | Astellas Pharma Inc. | Dérivé de benzimidazole |
DE102011083725A1 (de) * | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
-
2013
- 2013-07-05 ES ES13734744.9T patent/ES2603258T3/es active Active
- 2013-07-05 CA CA2878485A patent/CA2878485A1/fr not_active Abandoned
- 2013-07-05 MX MX2015000347A patent/MX2015000347A/es unknown
- 2013-07-05 AU AU2013289344A patent/AU2013289344A1/en not_active Abandoned
- 2013-07-05 WO PCT/EP2013/064257 patent/WO2014009274A1/fr active Application Filing
- 2013-07-05 US US14/414,386 patent/US9512169B2/en not_active Expired - Fee Related
- 2013-07-05 CN CN201380036684.4A patent/CN104428309B/zh not_active Expired - Fee Related
- 2013-07-05 EA EA201500112A patent/EA201500112A1/ru unknown
- 2013-07-05 JP JP2015520927A patent/JP6196302B2/ja not_active Expired - Fee Related
- 2013-07-05 EP EP13734744.9A patent/EP2872524B1/fr active Active
- 2013-07-05 KR KR20157002707A patent/KR20150036319A/ko not_active Application Discontinuation
- 2013-07-05 AP AP2014008179A patent/AP2014008179A0/xx unknown
- 2013-07-05 BR BR112015000443A patent/BR112015000443A2/pt not_active IP Right Cessation
- 2013-07-05 PE PE2015000018A patent/PE20150353A1/es not_active Application Discontinuation
- 2013-07-10 UY UY0001034899A patent/UY34899A/es not_active Application Discontinuation
- 2013-07-10 AR ARP130102438A patent/AR092025A1/es unknown
- 2013-07-10 TW TW102124795A patent/TW201402596A/zh unknown
-
2015
- 2015-01-05 IL IL236581A patent/IL236581A0/en unknown
- 2015-01-07 TN TNP2015000007A patent/TN2015000007A1/fr unknown
- 2015-01-07 MA MA37742A patent/MA37742B1/fr unknown
- 2015-01-08 CL CL2015000039A patent/CL2015000039A1/es unknown
- 2015-01-09 EC ECIEPI2015868A patent/ECSP15000868A/es unknown
- 2015-01-09 PH PH12015500062A patent/PH12015500062A1/en unknown
- 2015-01-09 CR CR20150007A patent/CR20150007A/es unknown
- 2015-01-09 DO DO2015000005A patent/DOP2015000005A/es unknown
- 2015-01-09 CO CO15004249A patent/CO7160008A2/es unknown
- 2015-02-09 ZA ZA2015/00920A patent/ZA201500920B/en unknown
- 2015-07-06 HK HK15106384.4A patent/HK1205743A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2878485A1 (fr) | 2014-01-16 |
US20150210734A1 (en) | 2015-07-30 |
DOP2015000005A (es) | 2015-02-15 |
MX2015000347A (es) | 2015-04-14 |
UY34899A (es) | 2014-02-28 |
AR092025A1 (es) | 2015-03-18 |
TW201402596A (zh) | 2014-01-16 |
IL236581A0 (en) | 2015-02-26 |
CN104428309B (zh) | 2016-09-14 |
CN104428309A (zh) | 2015-03-18 |
AU2013289344A1 (en) | 2015-02-05 |
AP2014008179A0 (en) | 2014-12-31 |
JP6196302B2 (ja) | 2017-09-13 |
BR112015000443A2 (pt) | 2017-06-27 |
CL2015000039A1 (es) | 2015-03-27 |
CO7160008A2 (es) | 2015-01-15 |
EP2872524A1 (fr) | 2015-05-20 |
EA201500112A1 (ru) | 2015-07-30 |
ZA201500920B (en) | 2017-01-25 |
KR20150036319A (ko) | 2015-04-07 |
PH12015500062A1 (en) | 2015-03-02 |
EP2872524B1 (fr) | 2016-08-24 |
TN2015000007A1 (en) | 2016-06-29 |
CR20150007A (es) | 2015-03-13 |
HK1205743A1 (en) | 2015-12-24 |
WO2014009274A1 (fr) | 2014-01-16 |
US9512169B2 (en) | 2016-12-06 |
MA37742B1 (fr) | 2016-12-30 |
ECSP15000868A (es) | 2016-01-29 |
PE20150353A1 (es) | 2015-03-28 |
JP2015522050A (ja) | 2015-08-03 |
ES2603258T3 (es) | 2017-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
MA42376B1 (fr) | Dérivés d'oxopyridine substitués | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA32226B1 (fr) | Compositions et leurs procedes de preparation et d'utilisation | |
MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
MA32230B1 (fr) | Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one | |
BR112013008140A8 (pt) | "compostos imidazotriazinona". | |
MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
CA2883210C (fr) | Composes aza bicycliques utilises comme agonistes du recepteur muscarinique m1 | |
MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
MA30914B1 (fr) | Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques. | |
UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
MA33566B1 (fr) | Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux | |
MA47356B1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA38925B1 (fr) | Dérivés de phénylalanine substitués | |
MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
MA35638B1 (fr) | 2-thiopyrimidinones | |
MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
MA34067B1 (fr) | Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer | |
ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
MA33679B1 (fr) | Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole | |
MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
MA37700B1 (fr) | N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments |